Krystal Biotech Inc. plans to raise up to $35 million in an initial public offering, according to a Securities and Exchange Commission filing late Monday. The Pittsburgh-based gene therapy company is a developer of treatments for dermatological diseases. With no revenue, Krystal reported a net loss of $1.2 million, or $5.89 a share, for 2016. Ladenburg Thalmann & Co. was listed as the underwriter for the IPO. Krystal intends to list on the Nasdaq under the ticker symbol “KRYS.”
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Latest posts by Market Watch (see all)
- Europe Markets: European stocks gain ground as German business sentiment strengthens - November 24, 2017
- Businesses eliminated hundreds of thousands of full-time jobs to avoid Obamacare mandate - November 24, 2017
- Gifts That Pay Off: Gifts that pay off: Turn your child into an early (and savvy) investor - November 24, 2017